Date published: 2026-5-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

KLHL13 Inhibitors

KLHL13 inhibitors belong to a distinctive class of chemical compounds that specifically target the Kelch-like family member 13 (KLHL13) protein. KLHL13 is a crucial component of the Kelch-like E3 ligase complex, which plays a pivotal role in the ubiquitin-proteasome system, a cellular mechanism responsible for the regulated degradation of proteins. The Kelch-like family of proteins, including KLHL13, serves as substrate adaptors within this system, facilitating the recognition and ubiquitination of specific protein targets. Inhibition of KLHL13 by these specialized compounds disrupts the normal functioning of the E3 ligase complex, resulting in altered ubiquitination patterns and subsequent changes in protein stability and turnover. KLHL13 inhibitors are designed to interact with the binding sites or active domains of KLHL13, thereby impeding its ability to recruit target proteins for ubiquitination. The modulation of KLHL13 activity by these inhibitors has downstream effects on the degradation of various cellular proteins, influencing diverse cellular processes. By selectively blocking the function of KLHL13, these inhibitors offer a valuable tool for researchers to investigate the intricate regulatory networks governed by the ubiquitin-proteasome system. Understanding the specific consequences of KLHL13 inhibition contributes to advancing knowledge of cellular processes influenced by targeted protein degradation. As research in this field progresses, the development of KLHL13 inhibitors provides a means to explore the broader implications of ubiquitin-proteasome system modulation in various biological contexts.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

MG-132 [Z-Leu- Leu-Leu-CHO]

133407-82-6sc-201270
sc-201270A
sc-201270B
5 mg
25 mg
100 mg
$60.00
$265.00
$1000.00
163
(3)

A peptide aldehyde that inhibits proteasomes and ubiquitin-mediated protein degradation.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$135.00
$1085.00
115
(2)

A boronic acid derivative that specifically inhibits 26S proteasome.

Ubiquitin E1 Inhibitor, PYR-41

418805-02-4sc-358737
25 mg
$360.00
4
(1)

An irreversible inhibitor of the ubiquitin-activating enzyme E1.

MLN 4924

905579-51-3sc-484814
1 mg
$286.00
1
(0)

A small molecule inhibitor of NEDD8-activating enzyme, affecting ubiquitin-like protein neddylation.

IU1

314245-33-5sc-361215
sc-361215A
sc-361215B
10 mg
50 mg
100 mg
$138.00
$607.00
$866.00
2
(0)

A small molecule that selectively inhibits the deubiquitinating enzyme USP14, affecting proteasome-associated deubiquitination.

Lactacystin

133343-34-7sc-3575
sc-3575A
200 µg
1 mg
$188.00
$575.00
60
(2)

A naturally occurring Streptomyces metabolite that irreversibly inhibits proteasome activity.

Epoxomicin

134381-21-8sc-201298C
sc-201298
sc-201298A
sc-201298B
50 µg
100 µg
250 µg
500 µg
$137.00
$219.00
$449.00
$506.00
19
(2)

A natural product that selectively inhibits the chymotrypsin-like activity of the proteasome.

Oprozomib

935888-69-0sc-477447
2.5 mg
$280.00
(0)

An bioavailable proteasome inhibitor that is structurally related to bortezomib.

Carfilzomib

868540-17-4sc-396755
5 mg
$41.00
(0)

An irreversible proteasome inhibitor used for cancer, showing selectivity for the chymotrypsin-like activity of the proteasome.

Withaferin A

5119-48-2sc-200381
sc-200381A
sc-200381B
sc-200381C
1 mg
10 mg
100 mg
1 g
$130.00
$583.00
$4172.00
$20506.00
20
(1)

A steroidal lactone from Withania somnifera that has been shown to inhibit the proteasomal activity.